Last reviewed · How we verify

Afrin

EMS · FDA-approved active Small molecule

Afrin is a Small molecule drug developed by EMS. It is currently FDA-approved. Also known as: oxymetazoline hydrochloride.

At a glance

Generic nameAfrin
Also known asoxymetazoline hydrochloride
SponsorEMS
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Afrin

What is Afrin?

Afrin is a Small molecule drug developed by EMS.

Who makes Afrin?

Afrin is developed and marketed by EMS (see full EMS pipeline at /company/ems).

Is Afrin also known as anything else?

Afrin is also known as oxymetazoline hydrochloride.

What development phase is Afrin in?

Afrin is FDA-approved (marketed).

Related